| Allergan is a pharmaceutical company focused on developing, manufacturing and commercializing pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Co. has three segments: United States Specialized Therapeutics, which includes products within the United States, including Medical Aesthetics, Medical Dermatology Eye Care and Neuroscience and Urology therapeutic products; United States General Medicine, which includes products within the United States that do not fall into the United States Specialized Therapeutics business units, including Central Nervous System; and International, which includes products sold outside the United States. |
When researching a stock like Allergan, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from AGN Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for AGN stock — the real life supply and demand for the stock over time — and examines that data in different ways. One of these ways is called the Relative Strength Index, or RSI. This popular indicator, originally developed in the 1970's by J. Welles Wilder, looks at a 14-day moving average of a stock's gains on its up days, versus its losses on its down days. The resulting AGN RSI is a value that measures momentum, oscillating between "oversold" and "overbought" on a scale of zero to 100. A reading below 30 is viewed to be oversold, which a bullish investor could look to as a sign that the selling is in the process of exhausting itself, and look for entry point opportunities. A reading above 70 is viewed to be overbought, which could indicate that a rally in progress is starting to get crowded with buyers. If the rally has been a long one, that could be a sign that a pullback is overdue.